Hubbry Logo
Mitochondrial shuttleMitochondrial shuttleMain
Open search
Mitochondrial shuttle
Community hub
Mitochondrial shuttle
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Mitochondrial shuttle
Mitochondrial shuttle
Mitochondrial shuttle
View on Wikipedia
from Wikipedia

The mitochondrial shuttles are biochemical transport systems used to transport reducing agents across the inner mitochondrial membrane. NADH as well as NAD+ cannot cross the membrane, but it can reduce another molecule like FAD and [QH2] that can cross the membrane, so that its electrons can reach the electron transport chain.

The two main systems in humans are the glycerol phosphate shuttle and the malate-aspartate shuttle. The malate/a-ketoglutarate antiporter functions move electrons while the aspartate/glutamate antiporter moves amino groups. This allows the mitochondria to receive the substrates that it needs for its functionality in an efficient manner.[1]

Shuttles

[edit]

In humans, the glycerol phosphate shuttle is primarily found in brown adipose tissue, as the conversion is less efficient, thus generating heat, which is one of the main purposes of brown fat. It is primarily found in babies, though it is present in small amounts in adults around the kidneys and on the back of our necks.[2] The malate-aspartate shuttle is found in much of the rest of the body.

Name In
To mitochondrion 		To ETC Out
To cytosol
Glycerol phosphate shuttle Glycerol 3-phosphate QH2 (~1.5 ATP) Dihydroxyacetone phosphate
Malate-aspartate shuttle Malate NADH (~2.5 ATP) Oxaloacetate[2]/aspartate

The shuttles contains a system of mechanisms used to transport metabolites that lack a protein transporter in the membrane, such as oxaloacetate.

Malate shuttle

[edit]
Main article: Malate-aspartate shuttle

The malate shuttle allows the mitochondria to move electrons from NADH without the consumption of metabolites and it uses two antiporters to transport metabolites and keep balance within the mitochondrial matrix and cytoplasm.

On the cytoplasmic side a transaminase enzyme is used to remove an amino group from aspartate which is converted into oxaloacetate, then malate dehydrogenase enzyme uses an NADH cofactor to reduce oxaloacetate to malate which can be transported across the membrane because of the presence of a transporter.

Once the malate is inside the matrix its converted back to oxaloacetate, which is converted to aspartate and can be transported back outside the mitochondria to allow the cycle to continue. The movement of oxaloacetate across the membrane transports electrons and is known as the outer ring. The inner ring primary function is not to move electrons but regenerate the metabolites.

Glycerol phosphate shuttle

[edit]
Main article: Glycerol phosphate shuttle

The transamination of oxaloacetate to aspartate is achieved through the use of glutamate. Glutamate is transported with aspartate via antiporter, thus as one aspartate leaves the cell, a glutamate enters. Glutamate in the matrix is converted into an a-ketoglutarate which is transported in an antiporter with malate. In the cytoplasmic side a-ketoglutarate is converted back into glutamate when aspartate is converted back to oxaloacetate.

Use against cancer

[edit]

Most cancer cells cause mutation in the bodies' metabolic activities to increase glucose metabolism in order to rapidly proliferate. Mutations that increase the cells metabolic activity and turn a normal cell into a tumor cell are called oncogenes. Cancer cells are unlike many other cells. They have very little vulnerabilities, but experiments in which the inhibition of transamination of malate-shuttle slowed proliferation due to the fact metabolism of glucose was being slowed.[3]

See also

[edit]

Notes and references

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Mitochondrial shuttle

View on Grokipedia
from Grokipedia
The mitochondrial shuttle systems are essential biochemical mechanisms that enable the transfer of reducing equivalents, such as electrons from cytosolic NADH produced during glycolysis, across the inner mitochondrial membrane into the mitochondrial matrix for oxidation in the electron transport chain, thereby supporting ATP production, since NADH cannot directly permeate this barrier. These shuttles link anaerobic glycolysis in the cytosol to aerobic respiration in the mitochondria, regenerating cytosolic NAD⁺ to sustain glycolysis while contributing to cellular energy homeostasis. The two primary shuttles in mammalian cells are the malate-aspartate shuttle (MAS) and the glycerol-3-phosphate shuttle (GPS), which differ in efficiency, tissue distribution, and ATP yield. The malate-aspartate shuttle (MAS) transfers reducing equivalents via malate and aspartate, yielding approximately 2.5 ATP per cytosolic NADH, and predominates in energy-demanding tissues like the heart, liver, kidney, and brain. In contrast, the glycerol-3-phosphate shuttle (GPS) transfers electrons via glycerol-3-phosphate, yielding about 1.5 ATP per cytosolic NADH by generating FADH₂, and is prominent in tissues such as skeletal muscle and brain. Mitochondrial shuttles integrate cytosolic and mitochondrial metabolism and respond to cellular stresses such as ischemia.

Overview

Necessity of shuttles

The is impermeable to NADH, preventing the direct entry of this molecule produced in the during into the . This barrier ensures that reducing equivalents from cytosolic NADH cannot freely cross to participate in the , necessitating alternative mechanisms for their transfer. Without shuttles, the accumulation of NADH in the would deplete the pool of NAD⁺ required for the glyceraldehyde-3-phosphate step in , halting the pathway and forcing cells to rely on anaerobic lactate production for NAD⁺ regeneration. Mitochondrial shuttles address this by transferring electrons from cytosolic NADH to mitochondrial NAD⁺ or , enabling the continued oxidation of glycolytic substrates under aerobic conditions and linking cytosolic to mitochondrial respiration. The concept of these shuttles emerged in the 1950s and 1960s through biochemical studies, including experiments on pigeon breast muscle mitochondria and liver extracts that demonstrated indirect oxidation of extramitochondrial NADH via intermediary metabolites. In eukaryotes, this compartmentalization maintains distinct balances between the (with a low NADH/NAD⁺ ) and mitochondria (with a higher ), supporting efficient production while avoiding inefficient mixing of coenzyme pools that could disrupt metabolic regulation.

General principles

Mitochondrial shuttles serve as essential mechanisms for transferring reducing equivalents derived from cytosolic NADH into the , where they can be utilized for energy production. Since the is impermeable to NADH, these shuttles employ intermediary carrier molecules, such as malate or glycerol-3-phosphate, to indirectly regenerate mitochondrial NADH or FADH₂ from cytosolic NADH. This process ensures that the electrons from cytosolic NADH, primarily generated during , can access the (ETC) without direct passage of the coenzyme across the membrane. At the core of these shuttles is the use of antiport transporters embedded in the , which facilitate the exchange of metabolites between the and matrix. These antiporters often operate in conjunction with the proton gradient established by the ETC, leveraging the to drive the uphill transport of certain metabolites, such as aspartate, out of the mitochondria. This energy-dependent exchange maintains the directionality of the shuttle, preventing futile cycles and ensuring efficient vectorial transport of reducing power into the . The transferred reducing equivalents enter the ETC, where they donate electrons to respiratory complexes, thereby contributing to the generation of a proton motive force across the inner membrane. This force powers ATP synthesis through chemiosmosis via ATP synthase, coupling the oxidation of cytosolic NADH to mitochondrial ATP production. The overall process can be represented by the equation: Cytosolic NADH+H++12O2→NAD++H2O\text{Cytosolic NADH} + \text{H}^+ + \frac{1}{2} \text{O}_2 \rightarrow \text{NAD}^+ + \text{H}_2\text{O} with reoxidation occurring in the mitochondria, yielding approximately 2.5 ATP per NADH oxidized at Complex I via . By facilitating this transfer, mitochondrial shuttles play a critical role in maintaining distinct NAD⁺/NADH gradients between the and , which is vital for regulating metabolic flux. The cytosolic compartment typically exhibits a higher NAD⁺/NADH to support dehydrogenase reactions in pathways like , while the matrix maintains a more reduced state to optimize ETC function. Disruptions in shuttle activity can thus impair and across cellular compartments.

Malate-Aspartate Shuttle

Key components

The malate-aspartate shuttle (MAS) involves several key enzymes and transporters that facilitate the transfer of reducing equivalents from cytosolic NADH to the . The primary enzymes include cytosolic (MDH1), which catalyzes the reversible reduction of oxaloacetate to malate using NADH; mitochondrial (MDH2), which performs the reverse reaction in the matrix to generate NADH; cytosolic aspartate aminotransferase (GOT1), which transaminates aspartate to oxaloacetate; and mitochondrial aspartate aminotransferase (GOT2), which converts oxaloacetate to aspartate using glutamate as the amino donor. Key transporters are the oxoglutarate/malate carrier (OGC; SLC25A11), which exchanges cytosolic malate for mitochondrial α-ketoglutarate across the inner membrane; and the aspartate-glutamate carriers (AGCs; SLC25A12 or SLC25A13), which export aspartate from in exchange for glutamate import coupled with a proton, making the process electrogenic and dependent on the proton-motive force. The main metabolites are malate and aspartate, which serve as carriers of reducing equivalents, along with oxaloacetate and α-ketoglutarate/glutamate for the steps. This setup allows for the net transfer of electrons without direct NADH transport, contrasting with simpler diffusion-based shuttles.

Reaction sequence

The malate-aspartate shuttle transfers reducing equivalents from cytosolic NADH, produced in , to mitochondrial NADH for oxidation in the , regenerating cytosolic NAD⁺ and yielding approximately 2.5 ATP per NADH via . The sequence starts in the , where MDH1 reduces oxaloacetate (OAA) to malate using NADH: [ \ce{OAA + NADH + H+ ->[MDH1] malate + NAD+} ] Malate is then transported into the via the OGC (SLC25A11) in exchange for α-ketoglutarate (α-KG). In the , MDH2 oxidizes malate back to OAA, producing NADH: [ \ce{malate + NAD+ ->[MDH2] OAA + NADH + H+} ] This NADH enters the at complex I. OAA is then transaminated to aspartate by GOT2, using glutamate and producing α-KG: [ \ce{OAA + glutamate ->[GOT2] aspartate + α-KG} ] Aspartate is exported to the via the AGC (SLC25A12/13), coupled with glutamate import and proton entry: [ \ce{aspartate_out + glutamate_in + H+_in} ] In the , GOT1 transaminates aspartate back to OAA using α-KG, regenerating glutamate: [ \ce{aspartate + α-KG ->[GOT1] OAA + glutamate} ] α-KG returns to the mitochondria via OGC in exchange for malate, closing the cycle. The net reaction is the oxidation of cytosolic NADH to mitochondrial NADH, driven by the proton gradient for aspartate export.

Glycerol-3-Phosphate Shuttle

Key components

The glycerol-3-phosphate shuttle primarily involves two key enzymes: cytosolic (GPD1, also known as cGPDH) and mitochondrial (GPD2, or mGPDH). GPD1 is a soluble NAD+-dependent located in the that catalyzes the reversible reduction of (DHAP), a glycolytic intermediate, to glycerol-3-phosphate (G3P) using NADH as the electron donor. In the shuttle function, GPD1 reduces DHAP to G3P while oxidizing NADH to NAD⁺. GPD2 is an integral embedded in the outer face of the , facing the , where it catalyzes the oxidation of G3P back to DHAP. This reaction reduces the enzyme's bound cofactor to FADH2, which subsequently transfers electrons directly to ubiquinone (coenzyme Q) in the , bypassing complex I. Unlike NADH-linked dehydrogenases, GPD2 operates unidirectionally in this context due to its linkage and orientation. The primary metabolites in the shuttle are DHAP and G3P, with DHAP serving as the substrate derived from and G3P acting as the diffusible carrier of reducing equivalents across the mitochondrial outer . No specific transporters are required for the , as the enzymatic reactions occur in the and G3P, being a small polar , freely diffuses through porins (such as VDAC) in the permeable outer . This simplicity contrasts with shuttle systems needing translocases for larger or charged intermediates.

Reaction sequence

The glycerol-3-phosphate shuttle facilitates the transfer of reducing equivalents from cytosolic NADH, generated during , to the mitochondrial via a cyclic series of reactions involving glycerol-3-phosphate as an intermediate carrier. This process regenerates NAD⁺ in the to sustain while delivering electrons to ubiquinone without requiring transport across the . The sequence begins in the with the enzyme glycerol-3-phosphate dehydrogenase 1 (GPD1), which catalyzes the reversible reduction of (DHAP), an intermediate from , to glycerol-3-phosphate (G3P), oxidizing NADH to NAD⁺ in the process. The reaction proceeds as follows: \ceDHAP+NADH+H+−>[GPD1]G3P+NAD+\ce{DHAP + NADH + H+ ->[GPD1] G3P + NAD+} G3P then diffuses freely across the outer mitochondrial membrane into the due to its small size and lack of charge. In the , or in close association with the , mitochondrial (mGPDH), a (FAD)-dependent , oxidizes G3P back to DHAP, reducing FAD to FADH₂. This step is represented by: \ceG3P+FAD−>[mGPDH]DHAP+FADH2\ce{G3P + FAD ->[mGPDH] DHAP + FADH2} The resulting FADH₂ subsequently transfers its electrons to ubiquinone (Q), reducing it to (QH₂), which integrates into the ubiquinone pool of the . This electron transfer is depicted as: \ceFADH2+Q−>FAD+QH2\ce{FADH2 + Q -> FAD + QH2} Finally, the regenerated DHAP diffuses back across the outer mitochondrial membrane into the cytosol, where it can be re-phosphorylated to glyceraldehyde-3-phosphate to continue the glycolytic pathway. The net effect of the shuttle can be summarized by the overall , which shows the oxidation of cytosolic NADH coupled to the reduction of ubiquinone: \ceCytosolic NADH+H++1/2 Q−>Cytosolic NAD++1/2 QH2\ce{Cytosolic\ NADH + H+ + 1/2\ Q -> Cytosolic\ NAD+ + 1/2\ QH2} Electrons introduced via QH₂ enter the at the ubiquinone site, proceeding through Complex III and Complex IV but bypassing Complex I, thereby generating fewer protons for the proton gradient and ultimately yielding less ATP per pair of electrons compared to NADH oxidation within .

Comparison and Regulation

Differences in efficiency and distribution

The malate-aspartate shuttle exhibits higher energetic efficiency compared to the glycerol-3-phosphate shuttle, yielding approximately 2.5 ATP molecules per cytosolic NADH oxidized, as it transfers reducing equivalents to mitochondrial NADH, which enters the at Complex I and drives the translocation of 10 protons across the . In contrast, the glycerol-3-phosphate shuttle yields about 1.5 ATP per NADH, since it generates FADH₂ that enters at Complex II, resulting in only 6 protons translocated. These ATP yields are calculated assuming an H⁺/ATP ratio of approximately 4 protons per ATP synthesized by , a value refined from the older 3:1 ratio based on structural and mechanistic studies of the enzyme since the early , with further insights from c-ring analyses in the 2010s. For NADH oxidation via Complex I, this equates to roughly 2.5 ATP (10 H⁺ / 4 H⁺ per ATP), while FADH₂ oxidation yields 1.5 ATP (6 H⁺ / 4 H⁺ per ATP). Tissue distribution of the shuttles reflects their physiological roles, with the malate-aspartate shuttle predominating in aerobic tissues such as the heart, liver, and kidney, where maximal ATP production is essential for sustained energy demands. The glycerol-3-phosphate shuttle is more prominent in fast glycolytic tissues like skeletal muscle and brain, facilitating rapid NADH reoxidation during bursts of activity. The malate-aspartate shuttle's higher efficiency comes at the cost of greater energy expenditure due to proton consumption in the transport of aspartate and glutamate across the mitochondrial membrane, making it suitable for tissues prioritizing ATP yield over speed. Conversely, the glycerol-3-phosphate shuttle is faster and simpler, involving fewer enzymatic steps, which allows quicker response to acute glycolytic flux in tissues requiring immediate energy, albeit with reduced overall efficiency. A similar glycerol-3-phosphate shuttle serves as the primary mechanism for NADH reoxidation during flight in , such as in muscle, where it supports high glycolytic rates. In humans, mitochondrial (GPD2) deficiency models, as studied in knockout mice, contribute to hepatic steatosis and altered , highlighting the shuttle's role in preventing obesity-related phenotypes.

Regulatory mechanisms

The regulatory mechanisms of mitochondrial shuttles operate primarily at enzymatic and allosteric levels to align NADH reoxidation with fluctuating metabolic demands, such as nutrient availability and oxygen levels. These controls ensure efficient transfer of reducing equivalents from cytosolic into mitochondria while preventing imbalances that could impair cellular energy production. Key enzymes and transporters in both the malate-aspartate shuttle (MAS) and glycerol-3-phosphate shuttle (G3PS) respond to metabolite ratios, ion gradients, and hormonal signals to modulate flux dynamically. In the MAS, activity is inhibited by a high mitochondrial NADH/NAD⁺ ratio, which reduces the driving force for and aspartate aminotransferase (AST), limiting NADH import and favoring cytosolic accumulation of reducing equivalents. AST activity is further modulated by Ca²⁺, which stimulates the aspartate-glutamate carrier (AGC) isoforms like aralar1 and citrin via their N-terminal EF-hand domains on the mitochondrial side, enhancing aspartate export independent of Ca²⁺ uptake. Hormonal regulation, such as , increases AST expression and activity by lowering α-ketoglutarate levels, thereby promoting aspartate formation and shuttle throughput in hepatocytes. Additionally, the AGC is sensitive to mitochondrial (ΔΨm), relying on the proton-motive force (approximately -220 mV) to drive electrogenic aspartate efflux in exchange for glutamate and proton influx, with reducing transport efficiency. For the G3PS, the cytosolic isoform of (cGPDH) is induced by (T3/T4), which upregulate its expression to support and reducing equivalent transfer, as evidenced in human fibroblasts and knockout models showing impaired energy expenditure. Insulin also induces cGPDH in certain cell types, such as lymphocytes, integrating it into pathways that link to and enhancing NAD⁺ regeneration during nutrient excess. Mitochondrial GPDH (mGPDH) activity rises with oxidation, as seen in obesity-resistant strains where elevated mGPDH correlates with higher NAD⁺/NADH ratios and increased β-oxidation rates in hepatocytes. Feedback regulation occurs via glycerol-3-phosphate (G3P) levels, where substrate accumulation acts as a rate-limiting signal, inhibiting mGPDH to prevent overload during high glycolytic flux. Both shuttles share common regulatory features, being upregulated in the fed state to support glycolytic NADH reoxidation and ATP production through enhanced NAD⁺ availability and shuttle optimization. In hypoxia, however, they are inhibited via hypoxia-inducible factor-1α (HIF-1α), which downregulates mitochondrial metabolism by inducing pyruvate dehydrogenase kinase 1 to block TCA cycle entry, promoting BNIP3-mediated mitophagy (reducing mitochondrial mass by over 50%), and miR-210 to impair , thereby shifting reliance to anaerobic glycolysis. Reciprocal regulation ensures tissue-specific dominance: the MAS prevails in oxidative tissues like heart and brain due to higher AGC and AST expression, while the G3PS predominates in glycolytic tissues such as white muscle and liver, driven by isoform-specific transcription. The peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α) orchestrates this by promoting and upregulating MAS components (e.g., via TFAM) in endurance-adapted oxidative fibers, while elevating G3PS enzymes in response to exercise-induced signals like AMPK and ROS to balance lactate clearance and energy demands. Shuttle flux follows Michaelis-Menten kinetics, where the rate depends on cytosolic NADH concentration: Shuttle rate=Vmax⁡⋅[NADH]cytKm+[NADH]cyt\text{Shuttle rate} = V_{\max} \cdot \frac{[\text{NADH}]_{\text{cyt}}}{K_m + [\text{NADH}]_{\text{cyt}}} This formulation captures saturation at high substrate levels, as modeled for MAS transporters and enzymes, ensuring controlled NADH delivery to mitochondria without overload.

Clinical Relevance

Role in metabolic disorders

Dysfunction in the mitochondrial shuttles, particularly the malate-aspartate shuttle, plays a significant role in the of by impairing glucose-stimulated insulin in pancreatic beta cells. Reduced activity of NADH shuttles, including the malate-aspartate pathway, has been observed in beta cells from models and patients, leading to diminished ATP production and insulin release, which contributes to . In , deficiencies in the glycerol-3-phosphate shuttle, mediated by mitochondrial GPD2, influence body and energy expenditure. Knockout of GPD2 in mice results in lower , reduced mass by 40%, and characterized by enhanced fat oxidation, leading to a lean despite normal food intake. Human genetic variants near the GPD2 locus, such as rare non-coding changes, have been linked to lower BMI in population studies, suggesting a protective role against . These findings indicate that GPD2 dysfunction shifts toward increased energy dissipation, potentially mitigating fat accumulation but altering overall metabolic . Mitochondrial diseases and tumors arising from mutations in shuttle components, such as the 2-oxoglutarate/malate carrier (OGC, SLC25A11) and aspartate-glutamate carrier (AGC, SLC25A13), can lead to neurological deficits. OGC mutations impair metabolite exchange across the and confer a predisposition to metastatic paragangliomas in pheochromocytoma-paraganglioma syndromes. Citrin deficiency due to SLC25A13 mutations disrupts the malate-aspartate shuttle in the liver, causing neonatal intrahepatic , adult-onset type II with , and neuropsychiatric symptoms such as delirium and disorientation. In mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes () syndrome, complex I deficiency overloads the malate-aspartate shuttle, resulting in cytosolic NADH accumulation and elevated lactate production. Overall, defects in mitochondrial shuttles promote a metabolic shift toward lactate production by limiting NADH transfer to the , mimicking the effect in non-oncologic contexts and contributing to in metabolic disorders. This redirection exacerbates energy deficits and in tissues reliant on efficient shuttle function, such as liver and muscle.

Targeting in cancer therapy

Cancer cells exhibiting the Warburg effect rely heavily on mitochondrial shuttles to regenerate NAD⁺, enabling sustained high glycolytic flux for proliferation. In Group 3 , particularly under hypoxic conditions mimicking the , cells depend on the malate-aspartate shuttle (MAS) and glycerol-3-phosphate shuttle (G3PS) for NADH reoxidation and . Therapeutic strategies exploit this vulnerability by inhibiting shuttle components, such as the aspartate aminotransferase with aminooxyacetic acid (AOAA) to block MAS or mitochondrial (mGPDH) with iGP-1 to disrupt G3PS. These inhibitors prevent NADH entry into mitochondria, causing cytosolic NADH accumulation, glycolytic impairment, elevated (ROS), and in cancer cells. A 2023 study on Group 3 organoids showed that combined blockade of MAS and G3PS with AOAA and iGP-1, alongside inhibition, drastically reduced tumor viability by over 90% and induced via cleaved caspase-3 activation, with further enhancement when paired with the metformin analog , doubling cell death rates. Preclinical investigations as of 2025 target SLC25A11 (2-oxoglutarate carrier, part of MAS) in using inhibitors like N-phenylmaleimide (KN-612), which suppresses tumorsphere growth by 80% through ATP depletion and bioenergetic switching. Shuttle inhibition also synergizes with by sparing T-cell mitochondrial function, thereby boosting anti-tumor immune responses without compromising effector T-cell metabolism. Unlike normal cells with lower glycolytic demands, cancer cells' elevated NADH production makes shuttles critical for survival, creating a selective therapeutic window that avoids widespread disruption in healthy tissues. In kidney cancer, a 2023 Harvard study revealed G3PS uncoupling, where cytosolic GPD1 flux outpaces mitochondrial GPD2 by 4.5-fold, diminishing intact shuttle reliance but emphasizing GPD1's role in lipid synthesis for tumor growth; low GPD2 expression sensitizes tumors to lipid pathway inhibitors, informing stratification.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC7693074/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC9525167/
  3. https://academic.oup.com/cardiovascres/article/91/3/382/306358
  4. https://doi.org/10.1002/iub.2367
  5. https://www.sciencedirect.com/science/article/pii/S1097276522007031
  6. https://www.sciencedirect.com/science/article/abs/pii/S0006295205006623
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC8657705/
  8. https://www.ncbi.nlm.nih.gov/books/NBK553175/
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC5737637/
  10. https://www.cell.com/cell-reports/fulltext/S2211-1247(23)01054-9
  11. https://www.nature.com/articles/s12276-024-01222-1
  12. https://omim.org/entry/138430
  13. https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2018.00687/full
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC3942692/
  15. https://pubchem.ncbi.nlm.nih.gov/pathway/METACYC:PWY-6118
  16. https://www.pnas.org/doi/10.1073/pnas.0712331105
  17. https://www.sciencedirect.com/science/article/pii/S0005272824005000
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC12229609/
  19. https://ecampusontario.pressbooks.pub/bioc2580/chapter/atp-synthase/
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC8362162/
  21. https://bio.libretexts.org/Bookshelves/Biochemistry/Book%253A_Biochemistry_Free_For_All_%28Ahern_Rajagopal_and_Tan%29/03%253A_Membranes/3.03%253A_Other_Considerations_in_Membranes
  22. https://www.sciencedirect.com/science/article/abs/pii/0022191065901162
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC6597300/
  24. https://www.embopress.org/doi/10.1093/emboj/20.18.5060
  25. https://www.sciencedirect.com/science/article/abs/pii/0003986188905991
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC4044302/
  27. https://www.sciencedirect.com/science/article/abs/pii/S0006291X85711709
  28. https://pubmed.ncbi.nlm.nih.gov/19049970/
  29. https://www.sciencedirect.com/science/article/pii/S0891584925008184
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC3010308/
  31. https://doi.org/10.3390/antiox10040609
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC2572303/
  33. https://www.jbc.org/content/279/53/55659.full.pdf
  34. https://www.medrxiv.org/content/10.1101/2020.11.13.20221812v1.full.pdf
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC7226361/
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC10031141/
  37. https://pubmed.ncbi.nlm.nih.gov/9309702/
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC3853754/
  39. https://www.nature.com/articles/s41419-023-06275-0
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC10635426/
  41. https://cancerci.biomedcentral.com/articles/10.1186/s12935-025-03813-y
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC11575104/
  43. https://www.cell.com/molecular-cell/fulltext/S1097-2765(23)00213-7
Add your contribution
Related Hubs
User Avatar
No comments yet.